These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32595451)

  • 1. P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis.
    Ruiz-Ruiz C; Calzaferri F; García AG
    Front Mol Neurosci; 2020; 13():93. PubMed ID: 32595451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purinergic P2X
    Mckenzie ADJ; Garrett TR; Werry EL; Kassiou M
    ACS Chem Neurosci; 2022 May; 13(10):1479-1490. PubMed ID: 35512313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis.
    Apolloni S; Parisi C; Pesaresi MG; Rossi S; Carrì MT; Cozzolino M; Volonté C; D'Ambrosi N
    J Immunol; 2013 May; 190(10):5187-95. PubMed ID: 23589615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic ablation of phospholipase C delta 1 increases survival in SOD1(G93A) mice.
    Staats KA; Van Helleputte L; Jones AR; Bento-Abreu A; Van Hoecke A; Shatunov A; Simpson CL; Lemmens R; Jaspers T; Fukami K; Nakamura Y; Brown RH; Van Damme P; Liston A; Robberecht W; Al-Chalabi A; Van Den Bosch L
    Neurobiol Dis; 2013 Dec; 60():11-7. PubMed ID: 23969236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases.
    Calzaferri F; Ruiz-Ruiz C; de Diego AMG; de Pascual R; Méndez-López I; Cano-Abad MF; Maneu V; de Los Ríos C; Gandía L; García AG
    Med Res Rev; 2020 Nov; 40(6):2427-2465. PubMed ID: 32677086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyotrophic Lateral Sclerosis Model.
    Azuma Y; Mizuta I; Tokuda T; Mizuno T
    Adv Exp Med Biol; 2018; 1076():79-95. PubMed ID: 29951816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
    Apolloni S; Amadio S; Montilli C; Volonté C; D'Ambrosi N
    Hum Mol Genet; 2013 Oct; 22(20):4102-16. PubMed ID: 23736299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs: newcomers into the ALS picture.
    Volonte C; Apolloni S; Parisi C
    CNS Neurol Disord Drug Targets; 2015; 14(2):194-207. PubMed ID: 25613506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.
    Alrafiah AR
    In Vivo; 2018; 32(5):983-998. PubMed ID: 30150420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD1, but not TDP-43.
    Tran LT; Gentil BJ; Sullivan KE; Durham HD
    J Neurochem; 2014 Aug; 130(3):455-66. PubMed ID: 24716897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why TDP-43? Why Not? Mechanisms of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis.
    Floare ML; Allen SP
    Neurosci Insights; 2020; 15():2633105520957302. PubMed ID: 32995749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.
    Apolloni S; Fabbrizio P; Parisi C; Amadio S; Volonté C
    Mol Neurobiol; 2016 Jan; 53(1):518-531. PubMed ID: 25482048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.
    Peviani M; Salvaneschi E; Bontempi L; Petese A; Manzo A; Rossi D; Salmona M; Collina S; Bigini P; Curti D
    Neurobiol Dis; 2014 Feb; 62():218-32. PubMed ID: 24141020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients.
    Hübers A; Just W; Rosenbohm A; Müller K; Marroquin N; Goebel I; Högel J; Thiele H; Altmüller J; Nürnberg P; Weishaupt JH; Kubisch C; Ludolph AC; Volk AE
    Neurobiol Aging; 2015 Nov; 36(11):3117.e1-3117.e6. PubMed ID: 26362943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misfolding at the synapse: A role in amyotrophic lateral sclerosis pathogenesis?
    Lum JS; Yerbury JJ
    Front Mol Neurosci; 2022; 15():997661. PubMed ID: 36157072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations.
    Jeon GS; Shim YM; Lee DY; Kim JS; Kang M; Ahn SH; Shin JY; Geum D; Hong YH; Sung JJ
    Mol Neurobiol; 2019 Mar; 56(3):2007-2021. PubMed ID: 29982983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis.
    Liu J; Prell T; Stubendorff B; Keiner S; Ringer T; Gunkel A; Tadic V; Goldhammer N; Malci A; Witte OW; Grosskreutz J
    Neurosci Lett; 2016 Sep; 630():77-83. PubMed ID: 27453058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal death in amyotrophic lateral sclerosis (ALS): what can we learn from genetics?
    Sreedharan J
    CNS Neurol Disord Drug Targets; 2010 Jul; 9(3):259-67. PubMed ID: 20406185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of amyotrophic lateral sclerosis.
    Liscic RM; Breljak D
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):370-2. PubMed ID: 20655970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.